Nuvectis Pharma Stock Analysis

Nuvectis Stock Analysis Notes

About 55.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.16. Nuvectis Pharma had not issued any dividends in recent years. Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company was incorporated in 2020 and is based in Fort Lee, New Jersey. Nuvectis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 8 people. To find out more about Nuvectis Pharma contact the company at 201 614 3150 or learn more at https://www.nuvectis.com.

Nuvectis Pharma Investment Alerts

Nuvectis Pharma Upcoming and Recent Events

Nuvectis Largest EPS Surprises

View All Earnings Estimates

Nuvectis Pharma Environmental, Social, and Governance (ESG) Scores

Nuvectis Stock Institutional Investors

Note, although Nuvectis Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Nuvectis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 123.07 M.

Nuvectis Profitablity

Management Efficiency

Nuvectis Pharma has return on total asset (ROA) of (0.6086) % which means that it has lost $0.6086 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4) %, meaning that it created substantial loss on money invested by shareholders. Nuvectis Pharma's management efficiency ratios could be used to measure how well Nuvectis Pharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.1 in 2025. Return On Capital Employed is likely to drop to -1.77 in 2025. Change To Liabilities is likely to gain to about 5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 4.3 M in 2025.

Technical Drivers

As of the 30th of January, Nuvectis Pharma secures the Downside Deviation of 10.3, mean deviation of 4.85, and Risk Adjusted Performance of 0.0093. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nuvectis Pharma, as well as the relationship between them.

Nuvectis Pharma Price Movement Analysis

Nuvectis Pharma Insider Trading Activities

Nuvectis Pharma Outstanding Bonds

Nuvectis Pharma Predictive Daily Indicators

Nuvectis Pharma Corporate Filings

Nuvectis Pharma Forecast Models

Nuvectis Pharma's time-series forecasting models are one of many Nuvectis Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Nuvectis Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Nuvectis Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Nuvectis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Nuvectis Pharma. By using and applying Nuvectis Stock analysis, traders can create a robust methodology for identifying Nuvectis entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Nuvectis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Nuvectis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Nuvectis Pharma stock analysis indicators help investors evaluate how Nuvectis Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Nuvectis Pharma shares will generate the highest return on investment. By understating and applying Nuvectis Pharma stock analysis, traders can identify Nuvectis Pharma position entry and exit signals to maximize returns.

When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.